Protein isolated from baker's yeast shows potential against leukemia cells

Researchers performed in vitro trials to test the effect of L-asparaginase on acute lymphoblastic leukemia cells and published the results in Scientific Reports.

By Karina Toledo  |  Agência FAPESP – An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer’s or baker’s yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.

Characterized by malignant alterations in the blood-forming stem cells in the bone marrow, ALL is the most common form of childhood cancer.

Findings from the research project, performed with FAPESP’s support, are described by scientists at the University of São Paulo’s School of Pharmaceutical Sciences (FCF-USP) and São Paulo State University’s Coastal Campus Bioscience Institute (IB-CLP-UNESP) in an article published in the journal Scientific Reports.

“In this study we characterize the enzyme L-asparaginase from S. cerevisiae. The results show this protein can efficiently annihilate leukemia cells with low cytotoxicity to healthy cells,” said Gisele Monteiro, a professor at FCF-USP and the principal investigator for the published study.

Production of the enzyme asparagine synthetase is deficient in ALL and several other types of cancer cells, which are therefore unable to synthesize the amino acid asparagine.

“This type of cell depends on extracellular sources of asparagine, an essential amino acid for the synthesis of proteins and hence of DNA and RNA. So it’s required for cell division,” Monteiro said. “The enzyme asparaginase depletes this amino acid in the extracellular medium, converting it into aspartate and ammonia. In patients with ALL, this leads to a sharp fall in serum levels of asparagine, hindering protein synthesis in malignant cells and inducing apoptosis, or programmed cell death.”

According to Monteiro, since the 1970s, ALL has been treated using an enzyme similar to the L-asparaginase described in the study but extracted from the bacterium Escherichia coli. When administered with other medications, treatment with the bacterial enzyme can achieve a remission rate of up to 80%. However, about 25% of patients have immune responses ranging from mild allergy to anaphylactic shock and are unable to use the biopharmaceutical as a result. 

As an alternative, two other drugs in the same class are internationally commercially available. One is PEG-asparaginase, a version of E. coli asparaginase that has been chemically modified to extend the drug’s effect by reducing excretion by the kidneys and formation of antibodies against the protein. As a result, the dose can be reduced, and adverse side effects are mitigated. The other similar drug, marketed as Erwinase, is also based on the enzyme asparaginase but is extracted from the bacterium Erwinia chrysanthemi.

“The patents held by the pharmaceutical companies concerned make the prices of these two drugs between 15 and 60 times higher than that of native E. coli asparaginase, which in fact is the only form approved for sale in Brazil by ANVISA, the National Health Surveillance Agency,” said Adalberto Pessoa Junior, a professor at the University of São Paulo’s School of Pharmaceutical Sciences (FCF-USP).

Another constraint on the therapeutic options open to Brazilian patients with ALL is that the only local manufacturer of E. coli asparaginase discontinued production in 2013.

Faced with a crisis in supply of the biopharmaceutical, several Brazilian scientists affiliated with various universities began working on projects designed to identify new sources of the enzyme, including the Thematic Project “Production of extracellular L-asparaginase: from bioprospecting to engineering of an anti-leukemia biopharmaceutical”, led by Pessoa Junior, with Monteiro and Marcos Antonio de Oliveira, a professor at IB-CLP-UNESP, as co-principal investigators.

“Our goal in this project wasn’t to produce the enzyme, but rather to find a new source of the biodrug in microorganisms for use in patients who develop resistance to the bacterial enzyme,” Oliveira said.

To this end, the researchers isolated fungi from several different Brazilian environments, such as the Cerrado and Caatinga, as well as marine and land environments in Antarctica. According to Oliveira, these organisms often secrete asparaginase into the extracellular medium in response to a shortage of nitrogen. “This lowers the cost of purifying the molecule for drug production, an important factor from an industrial standpoint,” he said.

The group also used bioinformatics tools to mine information on the genomes of several microorganisms from international databases. In this manner, they identified a gene responsible for producing an enzyme that closely resembles the enzymes found in E. coli and E. chrysanthemi, but with a number of advantages, in the genome of S. cerevisiae.

According to Iris Munhoz Costa, the first author of the study, many essential cellular processes are same in yeast and humans. This is because yeast is eukaryotic: its cells have a membrane-bound nucleus that contains the genetic material, whereas bacteria are prokaryotic and do not. This is believed to be why L-asparaginase induces a more moderate immune response than bacterial enzymes do.

The gene of interest from L-asparaginase was cloned, and the researchers used genetic engineering to make E. coli express large amounts of the enzyme originally found in yeast.

“We were able to obtain the recombinant protein,” Costa said. “We then performed studies to characterize its secondary structure and identify important regions called catalytic sites. Finally, we evaluated its efficacy in vitro.”

The enzyme was tested in three different cell lineages: leukemia cells incapable of producing asparagine at normal levels (MOLT4); another line of leukemia cells, in this case capable of producing asparagine at normal levels (REH); and non-malignant cells, used as a control (HUVECs).

These three different cell lineages were subdivided into two groups. One was treated with the commercially available E. coli enzyme, and the other was treated with L-asparaginase from yeast.

“The bacterial enzyme killed about 90% of the MOLT4 human leukemia cells and displayed low toxicity to the healthy HUVEC cells, killing only 10%,” Monteiro said. “The yeast enzyme killed between 70% and 80% of the MOLT4 cells and displayed less than 10% toxicity for HUVEC cells. Neither was significantly effective against REH cells.”

In her view, the results are encouraging, in contrast with those of studies performed with the same enzyme in the 1970s. At that time, the tests involved a version of the protein extracted directly from yeast and containing many impurities.

Much of the work described in the article was done by Costa for her master’s degree, with a scholarship from FAPESP and supervision by Monteiro.

PhD student Leonardo Schultz da Silva, Oliveira’s supervisee, with a scholarship from FAPESP, contributed to structural analysis of the protein.

The group’s next step is to perform new in vitro trials with different cell types to evaluate the immune response and toxicity. If the results are positive, the first tests in animals may be next. The researchers are also studying possible modifications that could be made to the molecule’s structure to increase anti-tumor activity and extend the enzyme’s half-life.

In addition to ALL, asparaginase is also used to treat rarer cancers such as lymphosarcoma, Hodgkin’s disease, chronic lymphocytic leukemia, reticulosarcoma and melanosarcoma.

The article “Recombinant L-asparaginase 1 from Saccharomyces cerevisiae: an allosteric enzyme with antineoplastic activity” (DOI: 10.1038/srep36239) can be read at nature.com/articles/srep36239.